https://www.selleckchem.com/products/cc-99677.html
Cardiac resynchronization therapy (CRT) improves symptoms and survival in patients with heart failure (HF). However, the CRT devices are costly and can impose a significant burden to the relatively constrained health budgets of middle-income countries such as Thailand. The aim of this study was to analyze the cost-effectiveness of CRT in combination with optimal medical therapy (OMT) relative to patients with OMT alone. A two-component model was used to analyze lifetime costs and quality-adjusted life-years (QALYs) from a healthcare pe
Like
Comment
Share
